Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by...

Novo Nordisk is preparing for a surge of generic semaglutide drugs in India. The company's India head stated they will monitor rivals' pric...

Novo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...

Glenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...

India's obesity drug market is experiencing rapid growth, driven by rising lifestyle diseases and the launch of blockbuster therapies. The ...

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outre...

Emcure Pharmaceuticals has taken a bold step in the realm of health and wellness by introducing Poviztra, a breakthrough in weight manageme...

Emcure Pharmaceuticals has launched Poviztra, a semaglutide injection for weight loss, becoming the first Indian company to exclusively dis...

At a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...

Pune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supp...

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the compan...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand n...

Novo Nordisk has partnered with Emcure Pharmaceuticals to bring Poviztra, their latest weight-loss medication, to the Indian market. This c...